Nebivolol
- Generic Name
- Nebivolol
- Brand Names
- Bystolic
- Drug Type
- Small Molecule
- Chemical Formula
- C22H25F2NO4
- CAS Number
- 118457-14-0
- Unique Ingredient Identifier
- 030Y90569U
- Background
Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than atenolol, propranolol, or pindolol. Nebivolol and other beta blockers are generally not first l...
- Indication
Nebivolol is indicated to treat hypertension.
- Associated Conditions
- Hypertension
- Associated Therapies
- -
A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2005-09-12
- Lead Sponsor
- Mylan Bertek Pharmaceuticals
- Target Recruit Count
- 260
- Registration Number
- NCT00158093
- Locations
- 🇺🇸
SFBC International, Inc., Miami, Florida, United States
Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients With Mild to Moderate Hypertension
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2005-09-14
- Lead Sponsor
- Mylan Bertek Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT00145236
- Locations
- 🇺🇸
Mylan Pharmaceuticals Inc., Morgantown, West Virginia, United States
The Effect of Nebivolol on Insulin Sensitivity
- First Posted Date
- 2005-08-02
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 54
- Registration Number
- NCT00125853
- Locations
- 🇬🇧
Imperial College London, Paddington, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath